ClinicalTrials.gg

Program

yinfenidone

Also written as “HEC585”, “HEC585 dose A” and “HEC585 dose B”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis · Pulmonary Fibrosis, led by Sunshine Lake Pharma.

Furthest: phase 3, since Jul 2, 20258 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sunshine Lake Pharma83 open or runningphase 3since Jul 2, 2025Mar 21, 2017Dec 2026phase 2 · NCT05139719

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 21, 2017First study: phase 1 study in Idiopathic Pulmonary FibrosisFirst studyNCT03092102 · 136 enrolled · United States
  2. Aug 7, 2020Phase 1 study in Idiopathic Pulmonary FibrosisNCT04512170 · 72 enrolled · China
  3. Sep 18, 2021Phase 2 study in Idiopathic Pulmonary FibrosisNCT05060822 · 270 enrolled · China
  4. Nov 17, 2021Phase 2 study in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)NCT05139719 · 110 planned · China
  5. Mar 29, 2022Phase 1 study in Idiopathic Pulmonary FibrosisNCT07588646 · 33 enrolled · China
  6. May 12, 20222 phase 1 studiesNCT05468346, NCT05383131
  7. Jul 2, 2025Phase 3 study in Idiopathic Pulmonary FibrosisNCT07082842 · 472 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)NCT05139719
  2. Jan 15, 2031Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT07082842

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07082842Idiopathic Pulmonary Fibrosis · China3RecruitingJan 15, 2031472
NCT05468346Healthy Volunteer · China1CompletedAug 14, 20226
NCT05383131Idiopathic Pulmonary Fibrosis · China1CompletedNov 30, 202133
NCT07588646Idiopathic Pulmonary Fibrosis · China1CompletedNov 30, 202133
NCT05139719Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) · China2RecruitingDec 2026110
NCT05060822Idiopathic Pulmonary Fibrosis · China2Active, not recruitingJul 16, 2025270
NCT04512170Idiopathic Pulmonary Fibrosis · China1CompletedAug 23, 202172
NCT03092102Idiopathic Pulmonary Fibrosis · United States1CompletedFeb 25, 2019136

How it is read

Names in the registry

  • “HEC585”, 6 entries
  • “HEC585 dose A”, 1 entry
  • “HEC585 dose B”, 1 entry
  • “[14C]-HEC585”, 1 entry

Codes read as this program: HEC585.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.